[{"address1": "3115 Merryfield Row", "address2": "Suite 300", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 465 6511", "website": "https://www.erasca.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 103, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan E. Lim M.D.", "age": 53, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 1099724, "exercisedValue": 0, "unexercisedValue": 291090}, {"maxAge": 1, "name": "Dr. David M. Chacko M.D.", "age": 41, "title": "CFO & Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2024, "totalPay": 728816, "exercisedValue": 0, "unexercisedValue": 1379634}, {"maxAge": 1, "name": "Dr. Shannon R. Morris M.D., Ph.D.", "age": 55, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 720640, "exercisedValue": 0, "unexercisedValue": 98644}, {"maxAge": 1, "name": "Dr. Nik  Chetwyn Ph.D.", "title": "Chief Operating Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Shoemaker Ph.D.", "age": 44, "title": "Chief Scientific Officer", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ebun S. Garner Esq., J.D.", "age": 53, "title": "General Counsel & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 607440, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lisa  Tesvich-Bonora Ph.D.", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian L. Baker CPA, M.S.", "age": 58, "title": "Senior Vice President of Finance", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Chandra D. Lovejoy M.S.", "age": 54, "title": "Chief Regulatory Affairs Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Minli  Xie Ph.D.", "title": "Senior Vice President of Pharmaceutical Development & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.81, "open": 6.06, "dayLow": 5.74, "dayHigh": 6.845, "regularMarketPreviousClose": 5.81, "regularMarketOpen": 6.06, "regularMarketDayLow": 5.74, "regularMarketDayHigh": 6.845, "payoutRatio": 0.0, "beta": 1.151, "forwardPE": -14.206456, "volume": 11715810, "regularMarketVolume": 11715810, "averageVolume": 2859809, "averageVolume10days": 7818390, "averageDailyVolume10Day": 7818390, "bid": 2.66, "ask": 4.51, "bidSize": 2, "askSize": 2, "marketCap": 1917891840, "fiftyTwoWeekLow": 1.01, "fiftyTwoWeekHigh": 6.845, "allTimeHigh": 24.47, "allTimeLow": 1.01, "fiftyDayAverage": 3.1294, "twoHundredDayAverage": 1.969075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1677784832, "profitMargins": 0.0, "floatShares": 167449544, "sharesOutstanding": 283711805, "sharesShort": 16962442, "sharesShortPriorMonth": 16250251, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0598, "heldPercentInsiders": 0.116730005, "heldPercentInstitutions": 0.81013, "shortRatio": 7.82, "shortPercentOfFloat": 0.0679, "impliedSharesOutstanding": 283711805, "bookValue": 1.226, "priceToBook": 5.5138664, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -127686000, "trailingEps": -0.43, "forwardEps": -0.47584, "enterpriseToEbitda": -12.777, "52WeekChange": 1.7023256, "SandP52WeekChange": 0.18594909, "quoteType": "EQUITY", "currentPrice": 6.76, "targetHighPrice": 11.0, "targetLowPrice": 2.0, "targetMeanPrice": 5.44444, "targetMedianPrice": 5.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 288400000, "totalCashPerShare": 1.017, "ebitda": -131317000, "totalDebt": 48293000, "quickRatio": 10.146, "currentRatio": 10.446, "debtToEquity": 13.882, "returnOnAssets": -0.17712, "returnOnEquity": -0.32004002, "freeCashflow": -67120624, "operatingCashflow": -98308000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ERAS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Erasca, Inc.", "longName": "Erasca, Inc.", "exchange": "NMS", "messageBoardId": "finmb_595471999", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 16.3511, "regularMarketPrice": 6.76, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1768006703, "regularMarketTime": 1767992400, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1626442200000, "postMarketChangePercent": 2.8106446, "postMarketPrice": 6.95, "postMarketChange": 0.18999958, "regularMarketChange": 0.95, "regularMarketDayRange": "5.74 - 6.845", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2859809, "cryptoTradeable": false, "fiftyTwoWeekLowChange": 5.75, "fiftyTwoWeekLowChangePercent": 5.6930695, "fiftyTwoWeekRange": "1.01 - 6.845", "fiftyTwoWeekHighChange": -0.08499956, "fiftyTwoWeekHighChangePercent": -0.01241776, "fiftyTwoWeekChangePercent": 170.23256, "earningsTimestamp": 1762981200, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.43, "epsForward": -0.47584, "epsCurrentYear": -0.29469, "priceEpsCurrentYear": -22.93936, "fiftyDayAverageChange": 3.6306002, "fiftyDayAverageChangePercent": 1.1601585, "twoHundredDayAverageChange": 4.790925, "twoHundredDayAverageChangePercent": 2.433084, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-16", "averageAnalystRating": "1.7 - Buy", "displayName": "Erasca", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]